© Copyright 2004-2021 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

PharmaInformatic provides
ADME Knowledge Bases
 and AI-based
 Expert Systems
for drug discovery
and toxicological
risk assessment.

Project results
of our research project
(Animal-free toxicity testing)
were presented at the

The company was founded in 2004 and is based in Emden, Germany.

  Get In Contact

    LinkedIn   Twitter

Replacement of animal tests by Artificial Intelligence

Once a suitable drug candidate is found, it needs to be checked if the drug is taken up and effective in humans. Our technology (expert systems) evaluates the pharmacokinetic profile of drugs in humans prior to clinical trials:

The evaluation with AI-based expert systems of two drugs for the treatment of COVID-19 showed that the effective concentration of Lopinavir would be too low to be effective in humans due to low oral bioavailability F and high protein binding PPB.

On the other hand, the predicted oral bioavailability F of Favipiravir was high and predicted protein binding PPB was low leading to a much higher effective concentration in humans (see current clinical trials results).

The optimal first-in-human dose (FiH) can be calculated more reliably than from animal studies, since drug uptake in animals and human often differs largely. This reduces attrition rates.

New expert system to evaluate Plasma Protein Binding by Artificial Intelligence:

PharmaInformatic has developed the largest and comprehensive annotated knowledge base on Plasma Protein Binding of compounds worldwide. It now contains more than 21.000 data records taken from more than 2.800 scientific publications. A validation study showed a high quality of prediction (more). The expert system is now available for drug research projects and toxicological risk assessment. Contact us for further details (email).

IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F evaluates oral bioavailability of future drugs in humans. The technology is used to optimise lead candidates. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. (research results).

Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail. Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.